SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Ventyx Biosciences, Inc. (VTYX) , forward earnings yield 0.64%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+141.9%).
- Forward P/E 155.6
- Analyst consensus target $33.86 (+141.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VTYX
Valuation Multiples
P/E (TTM)0.0
Forward P/E155.6
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.97
Forward EPS (Est.)$0.09
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield0.64%
Dividend Yield0.00%
Analyst Target$33.86 (+141.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.09 |
$0.00 |
$-4.47M |
- |
| 2020 |
$-0.57 |
$0.00 |
$-28.53M |
- |
| 2021 |
$-1.55 |
$0.00 |
$-78.37M |
- |
| 2022 |
$-2.06 |
$0.00 |
$-107.96M |
- |
| 2023 |
$-3.30 |
$0.00 |
$-192.96M |
- |
| 2024 |
$-1.97 |
$0.00 |
$-135.12M |
- |
